Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, Seligmann J, De Baere T, Osterlund P, Yoshino T, Martinelli E; ESMO Guidelines Committee. Electronic address: [email protected]. Cervantes A, et al. Among authors: yoshino t. Ann Oncol. 2023 Jan;34(1):10-32. doi: 10.1016/j.annonc.2022.10.003. Epub 2022 Oct 25. Ann Oncol. 2023. PMID: 36307056 Free article. No abstract available.
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.
Shah MA, Yoshino T, Tebbutt NC, Grothey A, Tabernero J, Xu RH, Cervantes A, Oh SC, Yamaguchi K, Fakih M, Falcone A, Wu C, Chiu VK, Tomasek J, Bendell J, Fontaine M, Hitron M, Xu B, Taieb J, Van Cutsem E. Shah MA, et al. Among authors: yoshino t. Clin Colorectal Cancer. 2023 Mar;22(1):100-110. doi: 10.1016/j.clcc.2022.11.002. Epub 2022 Nov 11. Clin Colorectal Cancer. 2023. PMID: 36503738 Clinical Trial.
Accelerating cancer omics and precision oncology in health care and research: a Lancet Oncology Commission.
Casolino R, Johns AL, Courtot M, Lawlor RT, De Lorenzo F, Horgan D, Mateo J, Normanno N, Rubin M, Stein L, Subbiah V, Westphalen BC, Lawler M, Park K, Perdomo S, Yoshino T, Wu J, Biankin AV; Lancet Oncology Commission on Cancer Omics and Precision Oncology. Casolino R, et al. Among authors: yoshino t. Lancet Oncol. 2023 Feb;24(2):123-125. doi: 10.1016/S1470-2045(23)00007-4. Lancet Oncol. 2023. PMID: 36725142 Free article. No abstract available.
Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials.
Taieb J, Sinicrope FA, Pederson L, Lonardi S, Alberts SR, George TJ, Yothers G, Van Cutsem E, Saltz L, Ogino S, Kerr R, Yoshino T, Goldberg RM, André T, Laurent-Puig P, Shi Q. Taieb J, et al. Among authors: yoshino t. Ann Oncol. 2023 Nov;34(11):1025-1034. doi: 10.1016/j.annonc.2023.08.006. Epub 2023 Aug 23. Ann Oncol. 2023. PMID: 37619846 Free PMC article.
Corrigendum to "Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3369 patients in the ARCAD database" Eur J Cancer. 2023 Jan;178:162-170.
Margalit O, Harmsen WS, Shacham-Shmueli E, Voss MM, Boursi B, Wagner AD, Cohen R, Olswold CL, Saltz LB, Goldstein DA, Hurwitz H, Tebbutt NC, Kabbinavar FF, Adams RA, Chibaudel B, Grothey A, Yoshino T, Zalcberg J, de Gramont A, Shi Q, Lenz HJ. Margalit O, et al. Among authors: yoshino t. Eur J Cancer. 2023 Nov;194:113339. doi: 10.1016/j.ejca.2023.113339. Epub 2023 Sep 28. Eur J Cancer. 2023. PMID: 37813779 No abstract available.
ICGC-ARGO precision medicine: familial matters in pancreatic cancer.
Milella M, Luchini C, Lawlor RT, Johns AL, Casolino R, Yoshino T, Biankin AV; ICGC-ARGO. Milella M, et al. Among authors: yoshino t. Lancet Oncol. 2022 Jan;23(1):25-26. doi: 10.1016/S1470-2045(21)00703-8. Lancet Oncol. 2022. PMID: 34973218 No abstract available.
2,109 results